Form 4: Viracta Therapeutics Director, Jane F. Barlow, Acquires Stock Options

Jane F. Barlow, a director of Viracta Therapeutics, acquired stock options for 50,000 shares at an exercise price of $0.569 on June 20, 2024.

Summary

• On June 20, 2024, Jane F. Barlow, a director of Viracta Therapeutics, Inc. (VIRX), acquired stock options for 50,000 shares.
• The exercise price of these options is $0.569 per share.
• The options vest monthly over a 12-month period, or fully upon the next annual stockholder meeting, contingent on continued service.
• The options expire on June 20, 2034.
• A Power of Attorney was executed on June 20, 2024, granting specific individuals the authority to act on behalf of Jane F. Barlow in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain information that would significantly sway investor sentiment positively or negatively. It's a neutral event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule of 1/12th per month or full vesting at the next annual stockholder meeting is a typical arrangement.
• The 10-year expiration date for the options is also a common industry practice.

Key Dates

Keywords

Viracta Therapeutics, Stock Options, Director, Jane F. Barlow, SEC Form 4, Beneficial Ownership, Power of Attorney, VIRX